While we identified some novel thought-provoking associations between DVL2 and multiple clinical prognostic indicators of breast cancer survival, we failed to observe these correlations in HER2+ patients who didn’t receive NAC (Supplementary Table 7). This evidence concerns the gene ERBB2 and breast carcinoma.